Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • DuoBody-CD40x4-1BB induces den...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity

DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity

Bibliographic Details
Main Authors: Maria Jure-Kunkel, Homer C Adams III, Kate Sasser, Mark Fereshteh, Alexander Muik, Isil Altintas, Friederike Gieseke, Aras Toker, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Dennis Verzijl, Kristina B Schoedel, Jordan M Blum, Bianca Sänger, Saskia M Burm, Eliana Stanganello, Vanessa M Spires, Fulvia Vascotto, Juliane Quinkhardt, Mustafa Diken, David P E Satijn, Sebastian Kreiter, Esther C W Breij
Format: Article
Language:English
Published: BMJ Publishing Group 2022-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/6/e004322.full
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://jitc.bmj.com/content/10/6/e004322.full

Similar Items

  • An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation
    by: Alexander Muik, et al.
    Published: (2022-12-01)
  • Correction: DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
    Published: (2022-09-01)
  • 1181 GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody®-CD40x4–1BB), exhibits in vivo antitumor activity and peripheral immune modulation
    by: Karsten Pilones, et al.
    Published: (2023-11-01)
  • 704 Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3x5T4 in vitro and in vivo in solid cancer models
    by: Kate Sasser, et al.
    Published: (2020-11-01)
  • A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice
    by: Nadja Salomon, et al.
    Published: (2020-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs